Dr. Huijuan Wang 王慧娟
Chief Physician, Associate Professor
Department of Integrated Traditional Chinese and Western Medicine Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Personalized comprehensive treatment and targeted therapy for lung cancer.
Dr. Wang holds a doctorate in oncology and serves as Chief Physician in the Department of Respiratory Medicine at Henan Cancer Hospital. Dr. Wang is affiliated with the Henan Lung Cancer Diagnosis and Treatment Center.
Professional roles
- Standing Committee Member, Youth Committee of the Chinese Society of Clinical Oncology (CSCO)
- Member, Immunotherapy Expert Committee of the Chinese Society of Clinical Oncology (CSCO)
- Member, International Association for the Study of Lung Cancer (IASLC)
- Chair, Youth Committee of the Lung Cancer Professional Committee, Henan Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Huijuan). Papers usually list the name as Huijuan Wang or Wang H.
Selected publications
63 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Pulm Med, 2025 (senior author): Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world. PubMed 39856706
- Asian J Surg, 2024 (senior author): The efficacy of different immunotherapy strategies to NSCLC patients after resistance to EGFR-TKIs: A retrospective study. PubMed 38871607
- Front Pharmacol, 2024 (senior author): Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer. PubMed 38655174
- Nat Commun, 2024 (senior author): Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial. PubMed 38374204
- BMC Cancer, 2023 (first author): Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study. PubMed 36997925
- Front Oncol, 2023 (senior author): Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib. PubMed 37035183
- Front Oncol, 2022 (senior author): Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations. PubMed 36119499
- Cancer Med, 2020 (first author): Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. PubMed 31769228
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion